Article Contents ::
Details About Generic Salt :: Hydroxycarbamide
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS |
| HYDROXYCARBAMIDE |
| RIBONUCLEOTIDE REDUCTASE INHIBITOR | ANTI-NEOPLASTIC |
| PK: A: Rapid D: Extensively M: Hepatic E: Urine |
|
Indications & Dose: CHRONIC MYELOID LEUKEMIA PO Adult 20-30mg/kg/day | POLYCYTHEMIA VERA PO Adult 15-20mg/kg/day, adjust dose according to platelet counts | SICKLE-CELL DISEASE PO Adult Initially 15mg/kg/day, increased by 5mg/kg/day q12wk according to response & blood counts, max 35mg/kg/day Child 2–18 yr: Initially 10–15mg/kg/day, increased by 5mg/kg/day q12wk according to response, usual dose 15–30mg/kg/day, max 35mg/kg/day | SOLID TUMORS PO Adult Intermittent therapy: 80mg/kg single dose every third day, continuous therapy: 20-30mg/kg/day | THALASSAEMIA PO Adult 8.2-10.3mg/kg/day | THROMBOCYTHEMIA PO Adult 15mg/kg/day, adjust dose according to platelet counts |
| Precautions: Renal/hepatic impairment, elderly
ADR: Serious: bone-marrow suppression, pulmonary edema, convulsions, hepatotoxicity, pancreatitis, peripheral neuropathy, renal impairment, pulmonary infiltrates, secondary leukemias, Others: hyperpigmentation, fever, dyspnea, anemia, headache, dizziness, drowsiness, hallucinations, GI disturbances DDI: Serious Carbamazepine decreases drug level, Interferon α increases risk of vasculitis, Stavudine/Didanosine leads to neuropathy & pancreatitis |
